Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
To print this article, all you need is to be registered or login on Mondaq.com.
As previously reported (
here and
here), the Advisory Council on the Implementation of National
Pharmacare (Council) was launched last month and has
invited all Canadians to provide their feedback on national pharmacare to "help shape the
Council's independent report to the Federal Government, to be
presented in spring 2019 ... which will provide the Government with
recommendations and a plan on how to move forward on national
pharmacare." Participants can provide their feedback online
until September 28, 2018, (by questionnaire or through a discussion forum) or in writing to the Council.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
